Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

  • Technology appraisal guidance
  • TA327
  • Published: 

History

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): final appraisal determination

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): final scope

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): final matrix

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): response to consultee and commentator comments on the draft scope (pre-referral)

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): response to consultee and commentator comments on the provisional matrix of consultees and commentators

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): Equality Impact Assessment - scoping

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): provisional matrix (pre-referral)

Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): draft scope (pre-referral)